Exelixis, Inc.'s STELLAR-303 zanzalintinib data disappoints in colorectal cancer with an FDA decision due in December 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results